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ABSTRACT
Objectives This study compared the efﬁcacy and
safety of subcutaneous (SC) versus intravenous (IV)
formulations of tocilizumab in patients with rheumatoid
arthritis with an inadequate response to disease-
modifying antirheumatic drugs (DMARD).
Methods Patients (n=1262) were randomly assigned
to receive tocilizumab-SC 162 mg weekly+placebo-IV
every 4 weeks or tocilizumab-IV 8 mg/kg every
4 weeks+placebo-SC weekly in combination with
traditional DMARD. The primary outcome was to
demonstrate the non-inferiority of tocilizumab-SC to
tocilizumab-IV with regard to the proportion of patients
in each group achieving an American College of
Rheumatology (ACR) 20 response at week 24 using a
12% non-inferiority margin (NIM). Secondary outcomes
were disease activity score using 28 joints (DAS28), ACR
responses, health assessment questionnaire scores and
safety assessments.
Results At week 24, 69.4% (95% CI 65.5 to 73.2) of
tocilizumab-SC-treated patients versus 73.4% (95% CI
69.6 to 77.1) of tocilizumab-IV-treated patients achieved
an ACR20 response (weighted difference between groups
−4.0%, 95% CI −9.2 to 1.2); the 12% NIM was met.
ACR50/70 responses, DAS28 and physical function
improvements were comparable between the tocilizumab-
SC and tocilizumab-IV groups. The safety proﬁles of
tocilizumab-SC and tocilizumab-IV were similar, and the
most common adverse event was infection. Injection-site
reactions (ISR) occurred more frequently in the tocilizumab-
SC group than in the tocilizumab-IV (placebo-SC) group.
No anaphylaxis was reported over the 24 weeks.
Conclusions Tocilizumab-SC 162 mg weekly
demonstrated comparable efﬁcacy to tocilizumab-IV
8 mg/kg. The safety proﬁle of tocilizumab-SC is consistent
with the known and well-established safety proﬁle of
tocilizumab-IV, with the exception of a higher incidence
of ISR, which were more common with tocilizumab-SC
administration.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive,
systemic autoimmune disease associated with joint
inﬂammation. Advances in RA treatments have been
made through the introduction of biological therap-
ies, including anti-tumour necrosis factor (TNF)
inhibitors, interleukin (IL)-1 receptor and IL-6
receptor (IL-6R) antagonists, an anti-CD20 agent
and a T-cell co-stimulation modulator.1 Although
these treatment options reduce disease activity, none
are effective in all patients. While a patient’s disease
status and overall health should be central when
choosing a therapy, differences in the route of
administration and safety proﬁles of the agent can
also affect the probability of a favourable response.1
Tocilizumab is a recombinant humanised anti-IL-
6R monoclonal antibody that blocks IL-6 from
binding to the soluble and membrane-bound IL-6R
and was initially developed as an intravenous (IV)
infusion. The efﬁcacy and safety of tocilizumab-IV
were previously demonstrated as monotherapy and
in combination with disease-modifying antirheumatic
drugs (DMARD) in adult patients with RA in ﬁve
phase 3 clinical trials.2 Tocilizumab is currently
approved as an IV formulation for the treatment of
RA, including in the USA and Europe.
A subcutaneous (SC) formulation of tocilizumab
would offer patients an additional option that may
allow self-administration. The tocilizumab-SC dose
was selected based on pharmacokinetic/pharmacody-
namic and limited efﬁcacy and safety data from phase
1/2 studies (see supplementary ﬁgure S1, available
online only).3 To characterise further the efﬁcacy and
safety of tocilizumab-SC, the SUMMACTA study
compared tocilizumab-SC 162 mg weekly versus
tocilizumab-IV 8 mg/kg every 4 weeks in adult
patients with RA who have had an inadequate
response to one or more DMARD.
PATIENTS AND METHODS
Participants
Patients (≥18 years of age) with RA (≥6 months,
revised 1987 American College of Rheumatology
(ACR) criteria) who met the following major criteria
were included: swollen joint count of 4 or greater
(66-joint count) and tender joint count of 4 or
greater (68-joint count) at screening and baseline,
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C-reactive protein (CRP) 10 mg/L or greater and/or erythrocyte
sedimentation rate (ESR) 28 mm/h or greater at screening.
Patients must have received one or more traditional DMARD at a
stable dose for 8 weeks or longer before baseline. Patients were
required to have had an inadequate response to DMARD (up to
20% of patients may have failed one or more anti-TNF). Before
random assignment, patients discontinued all biological
DMARD, including etanercept for 2 weeks or longer and inﬂixi-
mab, certolizumab, golimumab or adalimumab for 8 weeks or
longer. Concomitant oral glucocorticoids (≤10 mg/day prednis-
one or equivalent) and non-steroidal anti-inﬂammatory drugs (up
to the maximum recommended dose) were permitted if patients
were on a stable dose for 4 weeks or longer before baseline.
Major exclusion criteria included ongoing rheumatic or
inﬂammatory joint diseases other than RA, any active infections,
history of malignancy, positive hepatitis B surface antigen or
hepatitis C antibody, serious allergies to biological agents, previ-
ous treatment with tocilizumab, alkylating agents or cell-
depleting therapies or treatment with any investigational agent
at less than 4 weeks of screening, and intra-articular or paren-
teral glucocorticoids or immunisation with a live/attenuated
vaccine less than 4 weeks before baseline. Tuberculosis screening
was managed according to local practice.
Study design
SUMMACTA was a 2-year, randomised, double-dummy, active-
controlled, parallel-group, phase 3 multicentre trial with a double-
blind period of 24 weeks followed by an open-label period of
72 weeks (results presented separately). Patients were stratiﬁed by
geographical region and body weight category (<60, ≥60 to
<100 or ≥100 kg). During the double-blind period, patients were
randomly assigned 1 : 1 to receive 162 mg of tocilizumab-SC
162 mg per week+placebo-IV every 4 weeks or tocilizumab-IV
8 mg/kg every 4 weeks+placebo-SC weekly for 24 weeks (see sup-
plement, available online only). Tocilizumab-SC/placebo injections
were administered by preﬁlled syringe. After the ﬁrst four treat-
ments, subcutaneous injections could be administered at home by
patients or caregivers; home injection information was recorded
on diary cards. Dose modiﬁcation to subcutaneously every
2 weeks or intravenously 4 mg/kg every 4 weeks or dose interrup-
tion was permitted for safety concerns.
Outcomes and assessments
The primary outcome was to evaluate the non-inferiority of
tocilizumab-SC 162 mg weekly to tocilizumab-IV 8 mg/kg regard-
ing the proportion of patients in each group who achieved an
ACR20 response at week 24. Secondary endpoints included the
proportion of patients who achieved an ACR50/70 response,
remission based on the disease activity score using 28 joints
(DAS28 <2.6) and a decrease from baseline of 0.3 or greater in
the health assessment questionnaire–disability index (HAQ-DI) at
week 24. Subgroup analyses for ACR responses and DAS28 remis-
sion were conducted across the three weight categories. Due to
the non-inferiority design, the per-protocol (PP) population was
used for the primary, secondary and subgroup analyses. The PP
population was a subset of the intent-to-treat (ITT) population
and excluded patients with major protocol violations that could
potentially affect efﬁcacy outcomes. All patients signed informed
consent documents, and the study was conducted in accordance
with the Declaration of Helsinki and good clinical practice.
Safety
The safety population included patients who received one or
more dose of tocilizumab and had one or more post-dose safety
assessment. Safety assessments included adverse events (AE),
laboratory assessments, physical examination and vital signs.
Laboratory monitoring was conducted at weeks 2 and 4 and
every 4 weeks thereafter.
Pharmacokinetics and pharmacodynamics
Patients who provided one or more evaluable pharmacokinetic
sample were included in the pharmacokinetic population. In the
main study, the observed pre-dose tocilizumab concentration
(Ctrough) over 24 weeks was assessed; in the pharmacokinetic
substudy at week 20, the mean area under the curve (AUC),
maximum plasma concentration (Cmax) and Ctrough. pharmaco-
dynamic parameters included CRP and ESR, were assessed as
analysed in the safety population.
Immunogenicity
Blood samples were taken at baseline and throughout the study
for anti-drug antibody assessment. Positive samples from the
initial screening assay were analysed by a conﬁrmation assay for
speciﬁcity. The assays were performed as previously described
using a bridging ELISA.4 If the conﬁrmation assay was positive,
an inhibition ELISA was performed to evaluate the neutralising
potential of the anti-tocilizumab antibody.
Statistical methods
The time point for the primary analysis of the ACR20 response
was week 24. To claim non-inferiority, the lower bound of the
95% CI for the difference in ACR responses (tocilizumab-SC
162 mg weekly minus tocilizumab-IV 8 mg/kg) had to be greater
than −12%. A non-inferiority margin of 12% was deﬁned based
on the results observed in the tocilizumab-IV trials.5–7
For the primary analysis, the 95% CI of the weighted differ-
ence in ACR responses between the groups at week 24 was
calculated using Cochran–Mantel–Haenszel analysis. This differ-
ence was adjusted for the stratiﬁcation factors of region and
body weight. For all secondary endpoints, the differences in
treatment effects and 95% CI were reported. Sample size deter-
mination is outlined in the supplement (available online only).
RESULTS
Patient disposition and baseline characteristics
Of the 1262 patients randomly assigned, 631 received
tocilizumab-SC 162 mg weekly+placebo-IV and 631 received
tocilizumab-IV 8 mg/kg+placebo-SC (ﬁgure 1). The PP popula-
tion comprised 1095 patients (n=558, tocilizumab-SC 162 mg
weekly; n=537, tocilizumab-IV 8 mg/kg). The most common
protocol violation leading to PP exclusion was a non-stable dose
of DMARD for both groups.
Patient baseline demographics and clinical characteristics were
balanced across the tocilizumab-SC and tocilizumab-IV groups
in the PP (table 1) and safety populations (data not shown). The
mean RA duration, tender joint counts, swollen joint counts and
DAS28 scores were comparable between groups.
The prevalence of previous and current medications for RA
was similar between groups. The proportion of patients who
had inadequate responses to anti-TNF inhibitors was 22.5% in
the tocilizumab-SC group and 21.6% in the tocilizumab-IV
group; 79.7% of the tocilizumab-SC group and 81.5% of the
tocilizumab-IV group received methotrexate.
Efﬁcacy
The study met its primary endpoint by demonstrating the non-
inferiority of tocilizumab-SC 162 mg weekly to tocilizumab-IV
8 mg/kg. The proportion of tocilizumab-SC patients achieving
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an ACR20 response at week 24 was 69.4% (95% CI 65.5 to
73.2); for tocilizumab-IV patients, it was 73.4% (95% CI 69.6
to 77.1; ﬁgure 2A). The difference between groups was −4.0%
(95% CI −9.2 to 1.2), conﬁrming the non-inferiority of
tocilizumab-SC to tocilizumab-IV. The robustness of the primary
endpoint analysis was supported by analysis in the ITT popula-
tion: −2.7% (95% CI −7.6 to 2.2; see supplementary ﬁgure S2,
available online only).
ACR20, ACR50 and ACR70 response rates over 24 weeks
were similar between groups (ﬁgure 2A). The weighted differ-
ences in the proportion of ACR50 and ACR70 responders at
week 24 were −1.8% (95% CI −7.5 to 4.0) and −3.8% (95%
CI −9.0 to 1.3), respectively.
The proportion of patients who achieved DAS28 remission
over 24 weeks was comparable between groups (ﬁgure 2B). The
weighted difference in the proportion of patients achieving
DAS28 remission at week 24 was 0.9% (95% CI −5.0 to 6.8).
In post-hoc analyses, the proportion of patients who achieved
simple disease activity index, clinical disease activity index and
Boolean remission were also similar between groups (see supple-
mentary ﬁgure S3, available online only).
The proportion of patients who achieved a decrease of 0.3 or
greater in HAQ-DI score from baseline was similar between
groups (ﬁgure 2C). The weighted difference in the proportion
of patients achieving a decrease of 0.3 or greater in HAQ-DI
score from baseline was −2.3% (95% CI −8.1 to 3.4).
The proportion of patients achieving an ACR20/50/70
response (ﬁgure 3A) or DAS remission (ﬁgure 3B) was similar
between the groups across the three body weights. The response
in the heaviest weight category (≥100 kg) of both arms was
lower and had more variation, which may be due to the lower
number of patients in this weight category.
Pharmacokinetics and pharmacodynamics
The pharmacokinetic proﬁles of tocilizumab following subcuta-
neous and intravenous dosing varied due to the different routes
of administration. Serum trough tocilizumab levels increased
more rapidly in the tocilizumab-SC group than in the
tocilizumab-IV group (see supplementary ﬁgure S4, available
online only). With subsequent dosing, the trough tocilizumab
levels plateaued by week 12 in both groups. The observed
steady-state Ctrough (±SD) at week 24 was 42 (±27.4) μg/mL
following tocilizumab-SC dosing and 18 (±14.2) μg/mL follow-
ing tocilizumab-IV dosing.
Despite higher trough tocilizumab levels for tocilizumab-SC,
the mean AUC and Cmax of tocilizumab at steady state were
higher for tocilizumab-IV (see supplementary ﬁgure S5, avail-
able online only). Thirty-four patients participated in a pharma-
cokinetic substudy with more frequent sampling at week 20; 26
patients had sufﬁcient data for analysis (tocilizumab-SC, n=13;
tocilizumab-IV, n=13) (see supplementary ﬁgure S5, available
online only). At steady state from weeks 20 to 24, the mean
AUC20–24wk was 30 168 μg h/mL for tocilizumab-SC and
41 304 μg h/mL for tocilizumab-IV. The mean Cmax values
(±SD) at week 20 were 52.7 (±27.3) μg/mL for tocilizumab-SC
and 233 (±117) μg/mL for tocilizumab-IV.
CRP levels decreased in both groups after the ﬁrst dose of tocili-
zumab (see supplementary ﬁgure S6, available online only).
Thereafter, in both groups, CRP remained below the upper limit of
normal (ULN; 0.99 mg/dL) to week 24. The time course of CRP
for tocilizumab-SC was comparable to that for tocilizumab-IV,
although there was a trend towards slightly lower CRP levels in the
tocilizumab-SC group. Similar results were observed for ESR (see
supplementary ﬁgure S7, available online only).
Safety
The safety proﬁle was similar between groups (safety popula-
tion), except for more injection-site reactions (ISR) in the
tocilizumab-SC group (table 2). Rates of AE, serious adverse
events (SAE) and discontinuation due to AE were similar
between groups. The proportion of patients in each group with
a dose modiﬁcation or interruption due to an AE was compar-
able (see supplementary table S1, available online only). The fre-
quency of infection was 36.0% in the tocilizumab-SC group and
Figure 1 Patient disposition over 24 weeks. TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab. AE, adverse events; qw, weekly.
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39.1% in the tocilizumab-IV group. The most common AE was
infection; among them, the most commonly reported preferred
term was upper respiratory tract infection (7.3% tocilizumab-SC
and 11.6% tocilizumab-IV). The most common SAE was infec-
tion (1.4% in both groups). Serious infections of pneumonia
occurred in two patients in each group and bacterial arthritis
occurred in two patients in the tocilizumab-IV group. The most
common reason for withdrawal due to AE in both groups was
infection (1.1% tocilizumab-SC and 1.3% tocilizumab-IV). No
obvious differences were observed between treatment groups
for incidences of AE and SAE across the three weight categories
(see supplementary table S2, available online only).
No deaths were reported for patients receiving tocilizumab-SC.
One death was reported in the tocilizumab-IV group, attributable
to sepsis due to bacterial arthritis.
Three SAE of malignancy (<1%) occurred in the
tocilizumab-SC group and one (<1%) in the tocilizumab-IV
group. In the tocilizumab-SC group, breast cancer was diag-
nosed in two patients and a brain neoplasm in one patient. In
the tocilizumab-IV group, squamous cell carcinoma was diag-
nosed in one patient.
ISR were more common in the tocilizumab-SC group
(10.1%) than in the tocilizumab-IV group (2.4%), in which
patients also received placebo-SC. All ISR were non-serious and
common terminology criteria for adverse events grade 1 or 2;
none required dose interruption or withdrawal.
No anaphylaxis events were reported. Five SAE were
observed within 24 h of infusion or injection and evaluated as
‘related’ to study treatment; of these, three were medically con-
sistent with hypersensitivity and led to early study withdrawal
(two events in the tocilizumab-SC group and one event in the
tocilizumab-IV group). All events resolved without sequelae.
After initiation of tocilizumab, the majority of shifts in ALT
and AST from normal at baseline were threefold or less the
ULN; ALT shifts occurred in more patients in the
tocilizumab-SC group compared with the tocilizumab-IV group
(46% vs 39%, see supplementary table S3, available online
only). No differences between groups were observed for ALT
and AST shifts from normal at baseline to a value between more
than three times and ﬁve times or less ULN, or from normal to
more than ﬁve times ULN. One patient in the tocilizumab-SC
group and three patients in the tocilizumab-IV group had sus-
tained consecutive ALTelevations (an elevation from the time of
the ﬁrst elevation to the last record). One patient in the
Figure 2 Disease activity and physical function over 24 weeks for
patients in the per-protocol (PP) population. (A) Proportion of patients
in the PP population treated with either subcutaneous tocilizumab
(TCZ-SC; n=558) or intravenous tocilizumab (TCZ-IV; n=537) achieving
20%, 50% and 70% improvements per American College of
Rheumatology criteria (ACR20, ACR50 and ACR70) over 24 weeks.
(B) Proportion of patients achieving remission based on disease activity
score using 28 joints (DAS28) based on erythrocyte sedimentation rate
(ESR <2.6) over 24 weeks. (C) Proportion of patients achieving a health
assessment questionnaire (HAQ) response (improvement of ≥0.3 from
baseline) over 24 weeks. qw, weekly.
Table 1 Baseline demographics (per-protocol population)
Tocilizumab-SC
162 mg
qw (n=558)
Tocilizumab-IV
8 mg/kg
q4w (n=537)
Sex, n (%)
Female 461 (82.6) 444 (82.7)
Age, years, mean (SD) 52.4 (12.29) 52.5 (12.50)
Weight, kg, mean (SD) 74.07 (18.73) 73.82 (18.99)
Weight group, n (%)
<60 kg 131 (23.5) 129 (24.0)
60–100 kg 374 (67.0) 358 (66.7)
≥100 kg 53 (9.5) 50 (9.3)
Duration of RA, years, mean (SD) 8.7 (8.18) 8.7 (7.94)
Tender joints (68-joint count), mean (SD) 27.5 (15.54) 28.8 (16.42)
Swollen joints (66-joint count), mean (SD) 15.1 (9.03) 16.8 (10.55)
HAQ-DI score, mean (SD) 1.6 (0.62) 1.7 (0.65)
Patient’s assessment of pain, mean (SD) 60.2 (22.48) 61.8 (21.86)
Patient’s global assessment of disease
activity, mean (SD)
67.3 (21.65) 67.5 (21.63)
Physician’s global assessment of disease
activity, mean (SD)
61.2 (17.91) 62.6 (18.55)
RF positive, n (%) 456 (73.5)* 465 (74.4)†
ACPA positive, n (%) 434 (72.2)‡ 471 (74.4)§
CRP level, mg/dL, mean (SD) 2.1 (2.22) 2.2 (2.25)
DAS28, mean (SD) 6.6 (1.00) 6.7 (1.01)
Patients receiving methotrexate,¶ n (%) 503 (79.7)** 514 (81.5)**
Patients receiving glucocorticoids at
baseline, n (%)
300 (53.8) 290 (54.0)
Previously failed anti-TNF treatment, n (%) 121 (21.7) 112 (20.9)
*Of patients tested in the safety population, n=620.
†Of patients tested in the safety population, n=625.
‡Of patients tested in the safety population, n=601.
§Of patients tested in the safety population, n=621.
¶Includes up to 6 months before the study screening and ongoing at baseline.
**Of the safety population, n=631.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, disease
activity score using 28 joints; DMARD, disease-modifying antirheumatic drug;
HAQ-DI, health assessment questionnaire–disability index; IV, intravenous; qw, every
week; q4w, every 4 weeks; RA, rheumatoid arthritis; RF, rheumatoid factor; SC,
subcutaneous; TNF, tumour necrosis factor.
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tocilizumab-SC group and two patients in the tocilizumab-IV
group had sustained consecutive AST elevations. Five patients
(0.8%) in the tocilizumab-SC group and seven patients (1.1%)
in the tocilizumab-IV group prematurely discontinued because
of elevated liver transaminases. Among patients with a low
neutrophil count after initiating treatment, most experienced
common terminology criteria grade 1 or 2 neutropenia (see sup-
plementary table S3, available online only). Grades 1 and 2
events of neutropenia were reported for a slightly higher pro-
portion of patients in the tocilizumab-SC group compared with
the tocilizumab-IV group. No differences were observed
between groups for grades 3 or 4 neutropenia. One patient in
the tocilizumab-SC group experienced a sustained consecutive
neutrophil decline. For patients with a low platelet count,
almost all events were grade 1. The proportion of patients with
an increase in total cholesterol from less than 200 mg/dL at
baseline to more than 200 mg/dL at the last observation was
slightly higher in the tocilizumab-SC group than in the
tocilizumab-IV group (50% vs 42%). The largest categorical
shift in total cholesterol (from <200 to ≥240 mg/dL) was more
common in tocilizumab-SC patients than in tocilizumab-IV
patients (7% vs 4%). Clinically relevant shifts in low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol and
triglyceride levels were similar between groups.
Immunogenicity
Five patients in each group were positive (0.8% and 0.8%)
for both the conﬁrmation and neutralising assays post-
baseline. No patients with serious hypersensitivity events
developed anti-tocilizumab antibodies. One patient in the
tocilizumab-SC group with anti-tocilizumab antibodies had an
ISR. No patients with detected anti-tocilizumab antibodies
withdrew because of an insufﬁcient therapeutic response or
loss of efﬁcacy (deﬁned as patients from the ITT population
who withdrew due to insufﬁcient therapeutic response or who
experienced an ACR50 or DAS–ESR-based European League
Against Rheumatism) good response before withdrawal).
Based on the limited number of patients who developed anti-
tocilizumab antibodies, no impact of antibodies on the
pharmacokinetics of tocilizumab was observed.
DISCUSSION
Tocilizumab-IV is an efﬁcacious therapy with an acceptable risk/
beneﬁt proﬁle for patients with RA. The SUMMACTA study ana-
lysed whether tocilizumab-SC 162 mg weekly was non-inferior to
tocilizumab-IV 8 mg/kg in patients with RA with an inadequate
response to DMARD, which may have included one or more
anti-TNF inhibitors. The primary endpoint was met by demonstrat-
ing that the ACR20 response at week 24 for patients treated
with tocilizumab-SC was non-inferior to that of patients treated
with tocilizumab-IV. The safety proﬁles of tocilizumab-SC and
tocilizumab-IV were similar, except for a higher incidence of ISR
more commonly observed with tocilizumab-SC administration.
The ACR20 response rate for the tocilizumab-IV patients in
the PP population was higher than that observed in previous
tocilizumab-IV studies.5–8 Baseline disease characteristics were
comparable with previous tocilizumab-IV studies, so the higher
Table 2 Safety summary (safety population)
Tocilizumab-SC
162 mg qw
(n=631) 289.82 PY
Tocilizumab-IV
8 mg/kg q4w
(n=631) 288.39 PY
AE
Total AE, n 1747 1697
Patients with ≥1 AE, n (%) 481 (76.2) 486 (77.0)
Discontinuation due to AE,
n (%)
30 (4.8) 42 (6.7)
SAE
Total SAE, n 34 43
Patients with ≥1 SAE, n (%) 29 (4.6) 33 (5.2)
SAE per 100 PY (95% CI) 11.73 (8.12 to 16.39) 14.91 (10.79 to 20.08)
SI
Total SI 9 9
Patients with ≥1 SI, n (%) 9 (1.4) 9 (1.4)
SI per 100 PY (95% CI) 3.11 (1.25 to 5.89) 3.47 (1.66 to 6.38)
Serious hypersensitivity
reactions*, n (%)
2 (<1) 3† (<1)
ISR
Patients with ISR, n (%) 64 (10.1) 15 (2.4)
ISR, n 168 94
Erythema, n (%) 28 (4.4) 5 (0.8)
Pain, n (%) 12 (1.9) 5 (0.8)
Pruritus, n (%) 14 (2.2) 0 (0)
Haematoma, n (%) 5 (0.8) 5 (0.8)
Dose interruption or study
withdrawal because of ISR, n
0 0
Death, n (%) 0 (0) 1 (<1)
*Serious hypersensitivity was defined as an SAE occurring during or within 24 h of
the injection or infusion, excluding ISR, and evaluated as ‘related’ to study treatment
by the investigator.
†Of the three events in the tocilizumab-IV group, one was cellulitis and one was
retinal artery occlusion; these two events were not considered consistent with a
serious hypersensitivity reaction.
AE, adverse event; ISR, injection-site reaction; IV, intravenous; PY, patient-years; qw,
every week; q4w, every 4 weeks; SAE, serious adverse event; SC, subcutaneous; SI,
serious infection.
Figure 3 Proportion of patients stratiﬁed by weight in the
per-protocol population treated with either subcutaneous tocilizumab
(TCZ-SC; n=558) or intravenous tocilizumab (TCZ-IV; n=537) (A)
achieving 20%, 50% and 70% improvements per American College of
Rheumatology criteria (ACR20, ACR50 and ACR70) over 24 weeks and
(B) achieving remission based on disease activity score using 28 joints
(DAS28) based on erythrocyte sedimentation rate (ESR <2.6) over
24 weeks. qw, weekly.
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ACR20 response rate in this study may reﬂect that all patients
received active tocilizumab treatment, whereas previous
tocilizumab-IV studies included a placebo group or other com-
parator during the double-blind phase.
The CRP time course was comparable between groups. There
was a trend towards slightly lower CRP levels in the
tocilizumab-SC group, which was consistent with the higher
Ctrough concentrations in the tocilizumab-SC group over
24 weeks. These results were similar to those of previous phase
1/2 studies for tocilizumab-SC 162 mg weekly, thus validating
the assumptions made for the dose assessed.
The safety proﬁles between groups were similar in this study
and consistent with previous studies of long-term administration
of tocilizumab-IV, with infections being the most common AE
and SAE;5–8 consistent with other subcutaneous RA treatments,
higher ISR rates were reported in tocilizumab-SC than in
tocilizumab-IV. The incidence rate (10.1%) of ISR in the
tocilizumab-SC group was similar to that reported at 24 weeks
in other studies in patients with RA who received subcutaneous
anti-TNF inhibitors.9 10
Comparison of the incidence of antibodies to tocilizumab-SC
with other subcutaneous RA therapies is difﬁcult because the
measurement of antibody positivity (including neutralising anti-
bodies) is highly dependent on assay sensitivity, speciﬁcity and
methodology. In this study, the proportion of patients in both
groups who developed anti-tocilizumab antibodies was low and
comparable; no correlation was observed between antibody
development and AE or clinical response. Therefore, the
immunogenicity potential following tocilizumab-SC treatment
was considered low based on available data.
A limitation of the data is that long-term efﬁcacy and safety
have not been explored. Longer observation from this study and
additional data from other studies with tocilizumab-SC will
provide further information related to immunogenicity and AE.
In summary, the non-inferiority of tocilizumab-SC 162 mg
weekly to tocilizumab-IV 8 mg/kg every 4 weeks was demon-
strated. Tocilizumab-SC demonstrated efﬁcacy and clinical safety
proﬁles comparable with those of tocilizumab-IV, with the
exception of a higher incidence of ISR more commonly seen
with tocilizumab-SC. The tocilizumab-SC formulation could
provide an additional, more convenient administration option
and opportunity for home injection for patients with RA.
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Correction notice This article has been corrected since it was published Online
First. Figure 2A has been amended, and the following sentence amended to read:
The most common AE was infection; among them, the most commonly reported
preferred term was upper respiratory tract infection (7.3% tocilizumab-SC and
11.6% tocilizumab-IV). The most common SAE was infection (1.4% in both groups).
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